Chicago Life Sciences Summit

Dr. Suzet McKinney, a nationally recognized public health expert, serves as Principal and Director of Life Sciences. In her role, Dr. McKinney leads the strategy to expand Sterling Bay’s footprint in life sciences nationwide, pursue grant programs for laboratory incubation and graduation space and advance the work of various Sterling Bay life sciences initiatives including Prysm Institute. Prior to joining Sterling Bay, Dr. McKinney was CEO and Executive Director of the Illinois Medical District (IMD) where she managed medical research facilities, labs, a biotech business incubator, universities, four hospitals, and more than 40 healthcare-related facilities. Before IMD, Dr. McKinney served as Deputy Commissioner for the Bureau of Public Health Preparedness and Emergency Response at Chicago Department of Health.

Allyson Hansen, MHA, CPXP has an extensive career leading complex healthcare organizations and ensuring they reach their potential in delivering high quality care while elevating the patient experience, improving operational efficiency and ensuring financial stability. As the CEO & Executive Director of the Illinois Medical District (IMD), Hansen leads with responsibility for strategic planning, vision, growth and daily operations. She is also tasked with fostering relationships and collaboration among partners and stakeholders across the 560 acre healthcare ecosystem. As the Chief Executive Hansen guides the District during a time of explosive growth and creativity, supporting a vibrant healthcare ecosystem that includes four anchor medical institutions and more than 40 health-related facilities. As a seasoned executive with over 20 years’ experience in academic, community and national healthcare systems, Hansen brings extensive experience in strategy development and execution, operational improvement and partnerships to the IMD. Hansen has the proven ability to successfully analyze an organization's critical business requirements, identify deficiencies and potential opportunities, and develop innovative and cost-effective solutions for enhancing competitiveness and improving performance. She moves easily from vision and strategy to implementation and follow-through, building in project management, accountability and managing for daily improvement practices to ensure goal attainment. Hansen developed expertise in planning and administering healthcare services across Chicago land at UChicago Medicine, Loyola Health System, UI Health and Advocate Health Care. Prior to joining the IMD, she was Managing Partner of The Red Penny Group, advising national healthcare systems, medical groups and investors on growth, integration, operations and strategic plans. Hansen holds a Master of Health Administration and Bachelor of Arts in Psychology from the University of South Carolina, and is trained in Lean Six Sigma, change management and is a certified Patient Experience Professional. She is trained in Co- Active Coaching and is a graduate of the Disney Institute for Healthcare Leadership. Hansen is an active volunteer and advises emerging leaders and supports their career growth in the Menttium corporate mentoring network. Hansen lives in west suburban La Grange, where she serves on the community advisory council of Lyons Township High School.

Michael T. Flavin is Special Advisor to the Executive Director of the Discovery Partners Institute (DPI) at the University of Illinois. He has a 50% time appointment and has worked on the development of the DPI since May of 2018, focusing on the commercialization of DPI R&D science team technologies, building the ventures group at DPI and assisting with the real estate aspects of the project. Dr. Flavin is also Visiting Research Professor at the University of Illinois College of Medicine where he is assisting faculty members in the College of Medicine with the discovery, development and commercialization of new therapeutics and medical devices. In addition, he has been Interim Director of UICentre for Drug Discovery and Visiting Research Professor in the College of Pharmacy where he oversaw a team of researchers focused on leveraging the drug discovery resources at the UIC campus toward the discovery and development of potential new medicines. He is also Managing Director of Flavin Ventures, an early stage venture creation firm focused on creating, financing and developing biotechnology companies. Established in 2002, Flavin Ventures has significant experience in the management of commercial R&D programs, product development, commercialization and alliances, capital raising, legal and governmental affairs and company management including start-up processes, M&A transactions and IPO financings. Dr. Flavin has been CEO of Shamrock Structures, a drug discovery services company he founded in 2003 to provide pharmaceutical researchers with access to technologies and expertise in protein crystallography, medicinal chemistry and cell biology to accelerate their lead compound discovery programs. Shamrock Structures’ technology-driven research services help pharmaceutical and biotechnology companies accelerate the drug discovery process. He has also been Chairman & CEO of Advanced Life Sciences, a biopharmaceutical company he founded in 1999 and built to a team of 35 professionals focused on the development of new drugs to fight infection, inflammation and cancer. Advanced Life Sciences completed a $35M IPO in 2005 with C.E.Unterberg, Towbin as the lead underwriter. During the IPO road show, Dr. Flavin and his team conducted over 120 meetings with biotechnology mutual funds, hedge funds and other investors in 16 cities in the U.S. and Europe. Subsequent to that, he led the team in completing a $25M PIPE in 2006 and a $20M PIPE in 2007 with Lazard Capital Markets as the placement agent after meeting with several biotechnology investor groups around the country. These funds were used to advance drugs through clinical trials, including Restanza TM (cethromycin), a novel once-a-day oral antibiotic in NDA-stage development for the treatment of respiratory tract infections including pneumonia. As a public company CEO at Advanced Life Sciences for six years, Dr. Flavin conducted quarterly conference calls with analysts and investors and oversaw the filing of quarterly 10Q and annual 10K submissions to the SEC. In 1987, Dr. Flavin founded MediChem Life Sciences. He established MediChem as a premier drug discovery and development services company for the pharmaceutical industry. Over 14 years, MediChem grew from a two-person operation to more than 240 employees, serving over 90 clients in drug discovery, including most of the world’s largest pharmaceutical companies and many leading biotechnology firms. In 1999, Dr. Flavin and his team completed a $30M equity and debt venture capital round led by Chase Capital Partners. In 2000, he oversaw the acquisition and integration of ThermoGen, a protein expression company, and Emerald Biostructures, a structural biology company, as MediChem subsidiaries. In 2000, MediChem completed a $54M IPO with UBS as the lead underwriter. Dr. Flavin and his team conducted over 100 meetings with biotechnology investment firms in the U.S. and Europe during the IPO road show. In 2001, Dr. Flavin oversaw the construction of a 110,000 square foot laboratory and office building in Woodridge, IL to house MediChem operations. As CEO of MediChem, he led the investor relations effort, conducting conference calls with analysts and investors and submitting required SEC filings. MediChem was acquired in 2002 by deCODE genetics (NASDAQ:DCGN) to build a complete “gene map to drug” business model. During his career as a public company CEO, Dr. Flavin made numerous presentations at investor conferences such as the JP Morgan Conference, the UBS Life Sciences Conference and the Lazard Capital Markets Life Sciences Conference on behalf of MediChem Life Sciences and Advanced Life Sciences. Dr. Flavin has 49 publications in scientific journals and 20 U.S. patents in the fields of organic chemistry, medicinal chemistry and biochemistry. He has been awarded several grants from the National Institutes of Health to further his research in anti-infective and anti-cancer drug discovery. Dr. Flavin is a frequent lecturer on topics related to scientific entrepreneurship at universities such as the University of Notre Dame, the University of Chicago and the University of Illinois Chicago. He is the recipient of several awards, including the Alumnus of the Year Award in 2018 from the University of Illinois College of Pharmacy, the Charles D. Hurd Lectureship at Northwestern University, the Sr. Margaret Wright Graduate Award from the University of Illinois, the Chicago Area Entrepreneurship Hall of Fame and the Year 2000 Illinois High Tech Award. Dr. Flavin received his B.S. degree in chemistry from Notre Dame and his Ph.D. degree in medicinal chemistry from University of Illinois Chicago. After completing his postdoctoral fellowship at Harvard in synthetic organic chemistry, he was a Senior Research Scientist at Baxter prior to founding MediChem.

Nina Dudnik is a scientist, entrepreneur, community builder, and impact-driven leader. As Founder and CEO of Seeding Labs, she made investments in research and university infrastructure in 34 countries from Colombia to Zimbabwe. Her experience encompasses corporate strategy and innovation, government affairs, business development, marketing and enterprise customer acquisition, international development, and genetic research. Nina has a PhD in molecular biology from Harvard University and was a Fulbright Scholar at the Africa Rice Center in Cote d’Ivoire. She has received numerous awards including the JFK New Frontier award, and was named one of the world’s 100 most influential people in biotechnology by Scientific American Worldview magazine in 2015. --

As managing principal for Chicago’s HDR architecture studio, Grace oversees the strategic vision, delivers design excellence and technical quality, and strengthens the firm’s presence in Chicago. Her over thirty-year career includes the development of mixed-use, science and education projects for both the public and private sector. Extremely active within the community, Grace has served on the board of directors for the Magnificent Mile Association, Chicago Gateway Green Association, and the Chicago Women in Architecture Foundation.

With more than 20 years of experience in development, design, engineering and construction, Jon Fayard has extensive expertise in all phases of Life Sciences, including R&D/discovery (incubator and startup), pre-clinical/clinical research, manufacturing, commercialization and post-market research. Fayard is a former COO and Certified Six Sigma Green Belt by the Quality Institute of America. He is well-versed in managing full scale project life cycle from his time on the Owner’s side to working for a developer and top tier brokerage firm, as well as a premier manufacturing company and in design-build construction. Fayard uses a diverse, open-minded approach to solving problems for his clients, allowing them to focus on research rare and genetic diseases while he and his team bring their facilities goals to life.

Mr. Pachucki is Founder and Principal of the IBT Group LLC, which focuses on creative urban developments in metropolitan areas. Current projects include 1200 Fulton, a full-block creative office, retail and entertainment complex in the West Fulton Market area of Chicago. Mr. Pachucki is responsible for strategic management of all development activities for IBT Group including pipeline, acquisition, financing, planning, leasing and project execution. He has over 30 years of real estate experience and has been involved in the development of over ten million of square feet of office, residential and retail space throughout the country during his career. Prior to the formation of the IBT Group, Mr. Pachucki started and oversaw retail development in the Midwest for Opus Group of Companies, a family owned real estate company which was one of the largest privately held real estate companies in the country. Prior to OPUS he spent several years with Balcor as Vice president where he was responsible for an extensive national portfolio of 2,000,000 square feet of commercial space and 60,000 residential units. An architect by training, Mr. Pachucki spent several years with at the time the largest architectural firm in Wisconsin, Mochon, Schutte, Hackworthy & Juerisson, where he was involved in various aspects of the design process for institutional and commercial buildings including airports, schools and residential projects. Mr. Pachucki graduated from the University of Wisconsin with a Bachelor of Science in Architecture and also completed graduate level studies at the University of Wisconsin Graduate School of Architecture and Urban Planning.

Mark brings 20 years of industry experience to the Firm and is a member of the Firm’s Executive Committee. As Head of the North American Transactions platform, he is responsible for overseeing the day-to-day operations of the North American Transactions group. In addition, he is responsible for sourcing transactions and forming joint venture relationships. Mark is also a member of the Firm’s Environmental, Social and Governance Committee and a Sponsor of the Harrison Street Network of Women (HS NOW) affinity group. Prior to joining Harrison Street, Mark was at Morgan Stanley within its Merchant Banking Real Estate Investing Group. While there, he sourced, underwrote and closed acquisition and joint venture opportunities in the US, Canada and Mexico for several of its funds. In this capacity, he analyzed potential acquisitions, development and redevelopment opportunities across the capital structure, property types and risk/return fund parameters. Mark graduated from the University of Wisconsin – Madison with a BBA in Real Estate and Urban Land Economics as well as Finance, Investments Banking. He is a member of the University of Wisconsin Real Estate Alumni Association.

Jim Adox is the Executive Managing Director of Venture Investors Health Fund and is located in Ann Arbor, Michigan. He joined Venture Investors in 2006 as a Managing Director and has 25 years of venture capital experience. Jim serves as Chairman of the Board of Directors of HistoSonics, Inc. and serves on the Boards of ViaLase, Inc. and Dvant Pharma Inc. He was previously Chairman of the Board of Directors of Tissue Regeneration Systems (TRS), where he was a co-Founder and the Company’s first CEO (acquired by Johnson & Johnson and Medtronic). He was a Board Observer of NeuMoDx, Inc. (acquired by Qiagen) and of LenSx, Inc. (acquired by Alcon.) Jim is the Vice-Chair on the University of Michigan’s College of Engineering Leadership Advisory Board and is a member of the Innovation Partnerships National Advisory Board. Jim previously served on the Board of the Michigan Venture Capital Association and was its Chairman from 2013- 2015. Jim has a B S and M S in Mechanical Engineering and an MBA with High Distinction from the University of Michigan. Jim is fluent in Spanish and is a competitive triathlete and five-time Ironman finisher.

With over 30 years of industry experience and 3 million sq. ft. of life science projects completed, Jamie Prevost leads Skyline's Life Science practice area. Jamie leverages his expertise to assist clients during the due diligence process by providing strategic and collaborative preconstruction insight. Since the early 2000’s, Jamie has led the construction of 60+ labs and over a dozen adaptive re-use projects. During his leadership of San Diego based Prevost Construction, Jamie grew revenues from $10million to $100M before being acquired by Skyline Construction in 2022. With offices in San Francisco, Seattle, Chicago, and now San Diego, Jamie leverages established project teams and existing customer relationships to serve the surging demand for life science construction expertise. With his knowledge of the unique constraints associated with adaptive reuse and traditional life science tenant improvements, clients often lean on Jamie and his team for feasibility studies during the site selection process to provide reliable cost and scheduling information for major redevelopment efforts. With an emphasis on lean construction techniques and a partnership mindset, project teams under Jamie’s leadership deliver superior results with an emphasis on providing a best-in-class customer experience.

Justin Boberg is SM&W’s Global Security Discipline Leader and Chicago Office Director, overseeing SM&W’s worldwide security group as well as a multi-discipline team in Chicago consisting of acoustical, audiovisual, IT, security and medical equipment design consultants. Over two decades of security experience, Justin has managed projects involving master planning, threat assessment, risk analysis, systems planning and design, and implementation for a variety of project types, large & small. His people-first approach allows him to assess and evaluate physical security from an objective standpoint and tailor integrated, effective security solutions to the needs of each client. Justin’s proven track record in the identification and development of mitigation techniques has been honed by his holistic methodology of providing balanced solutions through architectural and operational recommendations to augment electronic measures in security program development and deployment.

As Head of U.S. Client Solutions for Property Management, our group’s focus is to help our Property Management business grow. I will do this in multiple ways: Lead and integrate several existing teams under the Client Solutions umbrella. Collectively, this team will oversee our go-to-market positioning for existing clients, support national new business development for new clients and expand existing client relationships within the company for Property Management. As we aim to enhance our connections with our clients and demonstrate CBRE’s differentiated value in the market through our people, our capabilities, and our service culture, our Client Solutions team will work closely with Marketing and Research on key initiatives to support this effort. Two critical priorities will be overseeing the Property Management brand initiative already underway with Marketing, and establishing our new Property Management Center of Excellence, designed to support all of our Market Leaders with greater tools and resources to drive growth. I will also be responsible for the creation of a national pitch team to support multi-market pursuits for major clients, including continued growth of Host, and enhancing our existing Client Account Management initiative to deepen our client relationships. In parallel to these efforts, I am also the national practice leader for our Property Management Life Sciences Practice Group, currently encompassing seven major markets across the country. Previously, I was the leader for our downtown Investor Services since early 2019, overseeing Property Management across the entire Chicago market as well as our Office Investor Leasing team. Prior to that, I started my career at CBRE within Project Management, most recently running the Midwest Region before stepping into the Investor Services portion of our Advisory business. #goodsmartdriven